Serina Therapeutics (SER) Profit After Tax (2018 - 2026)

Serina Therapeutics has reported Profit After Tax for 8 years, with the latest figure at -$3.6 million in Q4 2025.

• Quarterly Profit After Tax fell 31.02% year-over-year to -$3.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$19.5 million (down 73.91% YoY) and the FY2025 annual result came in at -$19.4 million, down 74.45% from the prior year.
• Profit After Tax climbed to -$3.6 million in Q4 2025 per SER's latest filing, from -$4.6 million in the prior quarter.
• Over five years, Profit After Tax peaked at $5.2 million in Q2 2024 and troughed at -$15.0 million in Q1 2024.
• A 5-year average of -$2.2 million and a median of -$2.5 million in 2021 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2021 and 2024: Profit After Tax tumbled 247500.0% in 2021, then surged 540.72% in 2024.
• Over 5 years, Profit After Tax stood at -$2.3 million in 2021, then decreased by 19.83% to -$2.7 million in 2022, then soared by 138.91% to $1.1 million in 2023, then slumped by 360.7% to -$2.7 million in 2024, then tumbled by 31.02% to -$3.6 million in 2025.
• According to Business Quant data, Profit After Tax over the past three periods registered -$3.6 million, -$4.6 million, and -$6.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.